Dawson J R, Thompson D S, Signy M, Juul S M, Turnbull P, Jenkins B S, Webb-Peploe M M
Br Heart J. 1985 Sep;54(3):313-20. doi: 10.1136/hrt.54.3.313.
Dopexamine, a new compound with postjunctional dopamine receptor activating and beta adrenoceptor agonist properties, was given to 10 patients with chronic heart failure at diagnostic cardiac catheterisation to investigate its acute haemodynamic and metabolic effects. The drug was administered by intravenous infusion in three incremental doses and produced significant dose related increases in cardiac index, stroke volume index, and heart rate and falls in systemic vascular resistance and left ventricular end diastolic pressure; aortic and pulmonary artery pressures were unchanged. Isovolumic phase (max dP/dt and KVmax) and ejection phase (peak aortic blood velocity, maximum acceleration of blood, and maximum rate of change of power with time during ejection) indices of myocardial contractility were all increased by dopexamine but these changes were hard to interpret in the presence of an increase in heart rate. Myocardial efficiency and ejection fraction were both increased and left ventricular end diastolic and end systolic volumes fell. These largely beneficial changes were achieved without a statistically significant increase in myocardial oxygen consumption or disturbance of myocardial metabolic function. Dopexamine was well tolerated but tremor was reported by two patients at the intermediate dose and mild chest pain by two patients at the high dose.
多培沙明是一种具有节后多巴胺受体激活特性和β肾上腺素能受体激动剂特性的新型化合物，在诊断性心导管插入术时给予10例慢性心力衰竭患者，以研究其急性血流动力学和代谢效应。该药物通过静脉输注以三种递增剂量给药，可使心脏指数、每搏量指数和心率显著增加，全身血管阻力和左心室舒张末期压力降低；主动脉和肺动脉压力未改变。多培沙明可增加心肌收缩力的等容相（最大dp/dt和KVmax）和射血相（主动脉峰值血流速度、血液最大加速度以及射血期间功率随时间的最大变化率）指标，但在心率增加的情况下，这些变化难以解释。心肌效率和射血分数均增加，左心室舒张末期和收缩末期容积减小。在心肌氧耗没有统计学显著增加或心肌代谢功能未受干扰的情况下，实现了这些大体上有益的变化。多培沙明耐受性良好，但两名患者在中等剂量时出现震颤，两名患者在高剂量时出现轻度胸痛。
